The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.
Megan Kilkeary, PharmD
Advertisement
Articles by Megan Kilkeary, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Daraxonrasib for Metastatic Pancreatic Cancer
2
FDA Grants Fast Track Designation to CK0803 for Amyotrophic Lateral Sclerosis
3
Yeast-Based Universal Flu Vaccine Fully Protects Mice Against 3 Influenza Strains
4
Pharmacists' Expanding Role in MASLD Screening and Care
5